Table 1.
Patients baseline characteristics.
| Characteristic | N (%) |
|---|---|
| Age, median (years) | 57 (51, 65) |
| Age (years) | |
| ≤65 | 56 (74.7%) |
| ＞65 | 19 (25.3%) |
| Sex | |
| male | 37 (49.3%) |
| female | 38 (50.7%) |
| Smoking status | |
| never or light smoking | 54 (72%) |
| heavy smoking | 21 (28%) |
| ECOG | |
| 0 | 36 (48%) |
| 1 | 39 (52%) |
| Histological subtype | |
| adenocarcinoma | 71 (94.6%) |
| non-adenocarcinoma | 4 (5.4%) |
| Brain metastasis | |
| no | 58 (77.3%) |
| yes | 17 (22.7%) |
| Liver metastasis | |
| no | 67 (89.3%) |
| yes | 8 (10.3%) |
| Pleural metastasis | |
| no | 48 (64%) |
| yes | 27 (36%) |
| Immune checkpoint inhibitors (ICIs) | |
| Pembrolizumab | 1 (1.3%) |
| chemotherapy and ICIs | 15 (20%) |
| RET inhibitors | |
| Pralsetinib | 11 (14.7%) |
| Selpercatinib | 4 (5.3%) |
| Cabozantinib | 6 (8%) |